secwatch.observer — SEC 8-K summary
======================================

Issuer:     IN8BIO, INC. (INAB)
CIK:        0001740279
Form:       8-K
Filed at:   2026-08-06T20:05:18+00:00
Accession:  0001193125-26-337944
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IN8bio reports Q2 2026 net loss of $4.8M; advances gamma-delta TCE platform with in vivo data expected H2 2026
--------------------------------------------------------------------------------

- Net loss of $4.8M ($0.25 per share) in Q2 2026, improved from $5.1M ($1.24) in Q2 2025.
- Cash of $18.0M at June 30, 2026, up from $13.2M a year earlier.
- DeltEx DRI in GBM: mOS >19.5 months, mPFS 13.0 months vs 6.6 months SOC.
- INB-619 gamma-delta TCE platform advancing; initial in vivo data expected H2 2026.
- Peer-reviewed publication in JCO and updated data at ASCO 2026 for DeltEx DRI in GBM.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1740279/000119312526337944/0001193125-26-337944-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1740279/000119312526337944/inab-20260806.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-337944

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer